Gilead Sciences, Inc. (GILD) Announces Results From Study Of Sovaldi® For Retreatment Of Chronic Hepatitis C In Patients Not Cured With Prior Antiviral Therapy
4/10/2014 9:12:31 AM
LONDON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from an open-label clinical trial (Study GS-US-334-0109) evaluating once-daily Sovaldi® (sofosbuvir) 400 mg tablets for the retreatment of chronic hepatitis C virus (HCV) infection among patients who failed prior therapy. These data will be presented in two oral sessions at the 49th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress 2014) in London.
Help employers find you! Check out all the jobs and post your resume.
comments powered by